ELEVAI Labs Acquires Exclusive License to Develop and Commercialize Novel Assets to Treat Obesity and Muscle Loss Prevention
The exclusive license is to two myostatin muscle loss prevention assets, which ELEVAI Labs plans to develop in combination with GLP-1 obesity treatments.
- The agreement adds two drug candidates to the company’s product pipeline, “EL-22”, a clinical-stage engineered probiotic expressing myostatin, and “EL-32”, a preclinical engineered probiotic expressing dual myostatin & activin-A.
- The exclusive license covers global rights excluding South Korea
- Clinical and preclinical data support advancing EL-22, a novel investigational myostatin asset for the treatment of obesity for an investigational new drug IND application in 2025.
- EL-22 has demonstrated a significant increase in body weight and restored muscle damage in preclinical mouse models, suggesting potential as a combination to glucagon-like peptide-1 “GLP-1” products to treat obesity.
ELEVAI Labs (NASDAQ: ELAB), announced that it has entered into an exclusive licensing agreement with MOA Life Plus Co., Ltd., a South Korean corporation, with the aim to develop and commercialize two novel assets for the treatment of obesity and muscle loss prevention.
The licensed assets include EL-22, a clinical-stage engineered probiotic expressing myostatin, and EL-32, a preclinical engineered probiotic expressing dual myostatin & activin-A. EL-22 has completed a Phase 1 clinical trial in South Korea, demonstrating it was generally well tolerated and safe in healthy volunteers. ELEVAI intends to evaluate EL-22 for efficacy and safety in combination with popular weight-loss therapeutics currently on the market, with the goal of decreasing fat mass while preventing the muscle wasting that commonly occurs with weight-loss drugs.
Jordan R. Plews, PhD, Co-Founder and Chief Executive Officer of the ELEVAI Labs commented on the agreement, stating:
“This license agreement represents a transformational and strategic milestone for Elevai. The adoption and use of other GLP-1 drugs has resulted in rapid weight loss and increases the desire for related aesthetic procedures linked to the side effects from these drugs, including significant unwanted muscle loss. We see the licensing of these two assets as an opportunity to provide an unmet need and expand into a large and growing multi-billion-dollar market.”
According to the CDC, 42% of adults suffer from obesity and could benefit from weight loss medication. Approved popular GLP-1 drugs such as Ozempic (semaglutide), Wegovy (semaglutide) or Mounjaro (tirzepatide) are expected to lead the anti-obesity market to $100 billion by 2030, according to Goldman Sachs Research. However, there remains a significant challenge as weight loss from the approved GLP-1 medications also results in collective loss of fat mass and lean muscle mass, which is critical for metabolism, strength, and mobility.
Based on preclinical data, ELEVAI believes that the assets it has licensed have the potential to significantly improve the standard of care for the treatment of obesity in combination with GLP-1 by preserving muscle mass while decreasing fat mass. The company plans to make an IND submission in 2025 and to initiate clinical trials in the U.S. to evaluate the probiotic approach of EL-22 and EL-32 in combination with one or more GLP-1 receptor agonists in obesity.
ELEVAI Labs Chief Medical Officer Dr. Tim Sayed added:
“Myostatin is a clinically validated target that has demonstrated potential in muscle mass and strength building and is currently being tested in combination with GLP-1 weight loss drugs. With our new additions, we believe that we have a differentiated, oral approach as compared to other myostatin strategies being tested in obesity. Our approach induces mucosal immunity through the body’s own anti-myostatin antibodies, which could have an important role in addressing the unmet medical need of obese patients, who need to preserve muscle while losing weight.”
Under the terms of the license agreement, the company obtained global rights outside of South Korea to develop and commercialize the assets in exchange for upfront cash and equity consideration. MOA is also eligible to receive milestone payments based upon the achievement of certain of the company’s development and sales milestones, and royalties on net sales of certain royalty-bearing products sold by ELEVAI and its affiliates or sublicensees.
Shares of ELEVAI Labs (NASDAQ: ELAB) last traded at $0.65. ELAB stock rose +5.64% in after-hours trading.
Learn more about ELEVAI Labs: Website | Investor Deck | ELAB Chart
Follow ELEVAI on Social Media: Instagram | Facebook | LinkedIn | Twitter | YouTube
Join the Discussion in the Wealthy VC Investor Group
Have a Stock Tip or New Story Suggestion? Email us at Invest@WealthyVC.com
Elevai Labs Inc. is a paid client of Wealthy VC.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.
